| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Nov 27, 2017 | AVDL Avadel Pharmaceuticals Plc | Stapleton Craig R | Director | Sell | 254,265 | $9.35 | $2,377,632.02 | -50.1% | |
| Nov 24, 2017 | SNOA Sonoma Pharmaceuticals, Inc. | Schutz James J | Chief Executive Officer | Buy | 254 | $5.05 | $1,282.70 | +1.7% | |
| Nov 22, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Shohet Stephen B. | Director | Sell | 7,862 | $18.94 | $148,895.27 | -24.6% | |
| Nov 22, 2017 | CPIX Cumberland Pharmaceuticals Inc | Bonner Michael | Chief Financial Officer | Buy | 250 | $7.81 | $1,952.50 | +1.6% | |
| Nov 21, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Gerst Diane G. | EVP, Qa &Regulatory Affairs | Sell | 523 | $18.81 | $9,839.25 | -1.6% | |
| Nov 21, 2017 | SNOA Sonoma Pharmaceuticals, Inc. | Miller Robert E | Chief Financial Officer | Buy | 2,000 | $5.03 | $10,065.00 | +9.1% | |
| Nov 21, 2017 | COLL Collegium Pharmaceutical, Inc | Fleming Alison B | Chief Technology Officer | Sell | 4,601 | $17.25 | $79,361.00 | -4.2% | |
| Nov 20, 2017 | JNJ Johnson & Johnson | Johnson & Johnson59 | 10% Owner | Sell | 18,367,346 | $2.75 | $50,510,201.50 | -100% | |
| Nov 20, 2017 | PCRX Pacira Biosciences, Inc. | Jones James B | SVP &Chief Medical Officer | Sell | 850 | $41.11 | $34,942.48 | -4.8% | |
| Nov 20, 2017 | CPIX Cumberland Pharmaceuticals Inc | Krogulski Kenneth55 | Director | Buy | 3,300 | $7.55 | $24,915.00 | +2.2% | |
| Nov 17, 2017 | LNTH Lantheus Holdings, Inc. | Healey Timothy G | SVP, Commercial | Sell | 11,314 | $21.51 | $243,400.34 | -14.6% | |
| Nov 17, 2017 | BHC Bausch Health Companies Inc. | De Schutter Richard U | Director | Buy | 10,000 | $14.33 | $143,300.00 | +11.8% | |
| Nov 17, 2017 | PCRX Pacira Biosciences, Inc. | Williams Kristen Marie76 | CAO And General Counsel | Sell | 10,000 | $40.00 | $400,021.43 | -19.0% | |
| Nov 16, 2017 | BHC Bausch Health Companies Inc. | Paulson John52 | Director | Buy | 344,216 | $14.40 | $4,955,505.64 | +1.7% | |
| Nov 16, 2017 | BHC Bausch Health Companies Inc. | Paulson John52 | Director | Sell | 344,216 | $14.39 | $4,952,820.76 | -1.6% | |
| Nov 16, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Shohet Stephen B. | Director | Sell | 7,862 | $18.04 | $141,861.93 | -24.6% | |
| Nov 16, 2017 | PRGO Perrigo Co Plc | Farrington Thomas | EVP And CIO | Sell | 213 | $87.26 | $18,585.32 | -6.8% | |
| Nov 15, 2017 | COLL Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Chairman, President And CEO | Sell | 50,000 | $15.53 | $776,500.00 | -8.2% | |
| Nov 15, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Gerst Diane G. | EVP, Qa &Regulatory Affairs | Sell | 523 | $17.77 | $9,291.57 | -1.6% | |
| Nov 15, 2017 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 9,900 | $73.05 | $723,191.04 | -42.9% | |
| Nov 15, 2017 | PCRX Pacira Biosciences, Inc. | Stack David M67 | CEO And Chairman | Sell | 58,885 | $38.34 | $2,257,708.20 | -22.5% | |
| Nov 14, 2017 | LNTH Lantheus Holdings, Inc. | Duffy Michael P | See Remarks | Sell | 11,917 | $21.63 | $257,787.35 | -7.3% | |
| Nov 14, 2017 | TLPH Talphera, Inc. | Edwards Mark G | Director | Buy | 30,000 | $1.90 | $56,970.00 | +25.0% | |
| Nov 14, 2017 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 40,000 | $40.37 | $1,614,800.00 | -1.3% | |
| Nov 13, 2017 | BCRX Biocryst Pharmaceuticals Inc | Sheridan William P67 | Senior VP - CMO | Sell | 64,310 | $4.72 | $303,543.20 | -72.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.